Quantitative Estimation of Anti Hypertension Combination by Ratio Subtraction Spectrophotometry Method.
Hydrochlorothiazide
Irbesartan
Ratio subtraction
Spectrophotometry ultraviolet
Journal
Open access Macedonian journal of medical sciences
ISSN: 1857-9655
Titre abrégé: Open Access Maced J Med Sci
Pays: North Macedonia
ID NLM: 101662294
Informations de publication
Date de publication:
15 Sep 2019
15 Sep 2019
Historique:
received:
09
06
2019
revised:
28
07
2019
accepted:
29
07
2019
entrez:
18
12
2019
pubmed:
18
12
2019
medline:
18
12
2019
Statut:
epublish
Résumé
Irbesartan and hydrochlorothiazide are a group of anti-hypertensive drugs that are very effective and safe to use to reduce blood pressure and oedema. The combination has a small active ingredient content so that if the treatment didn't meet the requirements for therapeutic doses, it not achieved to the maximum therapy. The research aims to the simultaneous determination of irbesartan and hydrochlorothiazide in tablets by Ratio subtraction spectrophotometry method. The absorption spectra and sample measurement in the Ratio subtraction method performed on Irbesartan at a wavelength of 247.6 nm and 273.6 nm for the Hydrochlorothiazide (HCT) using 0.1 N NaOH as a solution. This method is validated with linearity, accuracy, and precision in intraday and interday, LOD and LOQ and applied in the determination of a mixture of irbesartan and hydrochlorothiazide in the dosage tablet. The validation test for IRB is 101.03 for accuracy, with a precision of 0.57; with precision testing at intraday 0.34 and interday 1.34, and LOD is 0.70 and LOQ is 2.12. Meanwhile, validation for HCT that the accuracy 100.34%; precision 0.89 and precision on intraday 1.20 and interday 1.18, and LOD 0.78 and LOQ 2.37 with IRB levels are 101.03 ± 0.63% and HCT is 100.59 ± 0.91%. The ultraviolet spectrophotometric method in subtraction ratio method was validated a method of linearity, accuracy, precision in intraday and interday, LOD, and LOQ and according to ICH guidelines and successfully applied for the determination simultaneous of irbesartan and hydrochlorothiazide in the tablet's dosage form.
Sections du résumé
BACKGROUND
BACKGROUND
Irbesartan and hydrochlorothiazide are a group of anti-hypertensive drugs that are very effective and safe to use to reduce blood pressure and oedema. The combination has a small active ingredient content so that if the treatment didn't meet the requirements for therapeutic doses, it not achieved to the maximum therapy.
AIM
OBJECTIVE
The research aims to the simultaneous determination of irbesartan and hydrochlorothiazide in tablets by Ratio subtraction spectrophotometry method.
METHODS
METHODS
The absorption spectra and sample measurement in the Ratio subtraction method performed on Irbesartan at a wavelength of 247.6 nm and 273.6 nm for the Hydrochlorothiazide (HCT) using 0.1 N NaOH as a solution. This method is validated with linearity, accuracy, and precision in intraday and interday, LOD and LOQ and applied in the determination of a mixture of irbesartan and hydrochlorothiazide in the dosage tablet.
RESULTS
RESULTS
The validation test for IRB is 101.03 for accuracy, with a precision of 0.57; with precision testing at intraday 0.34 and interday 1.34, and LOD is 0.70 and LOQ is 2.12. Meanwhile, validation for HCT that the accuracy 100.34%; precision 0.89 and precision on intraday 1.20 and interday 1.18, and LOD 0.78 and LOQ 2.37 with IRB levels are 101.03 ± 0.63% and HCT is 100.59 ± 0.91%.
CONCLUSION
CONCLUSIONS
The ultraviolet spectrophotometric method in subtraction ratio method was validated a method of linearity, accuracy, precision in intraday and interday, LOD, and LOQ and according to ICH guidelines and successfully applied for the determination simultaneous of irbesartan and hydrochlorothiazide in the tablet's dosage form.
Identifiants
pubmed: 31844461
doi: 10.3889/oamjms.2019.750
pii: OAMJMS-7-2940
pmc: PMC6901840
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2940-2946Informations de copyright
Copyright: © 2019 Muchlisyam Bachri, Masfria Masfria, Syahputra Syahputra, Hafid Hafid.
Références
Drugs. 2006;66(8):1107-15
pubmed: 16789795
J Pharm Biomed Anal. 2002 Jun 20;29(1-2):299-305
pubmed: 12062690
Spectrochim Acta A Mol Biomol Spectrosc. 2014 Nov 11;132:446-51
pubmed: 24887506
Spectrochim Acta A Mol Biomol Spectrosc. 2014 Apr 5;123:473-81
pubmed: 24424258
Spectrochim Acta A Mol Biomol Spectrosc. 2012 Oct;96:259-70
pubmed: 22683662
J Hypertens. 2007 Jun;25(6):1105-87
pubmed: 17563527
J Hum Hypertens. 1999 Oct;13(10):683-7
pubmed: 10516738
Curr Vasc Pharmacol. 2009 Apr;7(2):120-36
pubmed: 19355995
Spectrochim Acta A Mol Biomol Spectrosc. 2014 Apr 24;124:292-9
pubmed: 24495837
Expert Rev Cardiovasc Ther. 2003 May;1(1):43-50
pubmed: 15030296